Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZX008 (Fenfluramine) in CDKL5 Deficiency Disorder (GEMZ)
NCT05064878Phase 3Active, not recruiting
- Sponsor
- Zogenix, Inc.
- Start
- Mar 2022
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of fenfluramine in CDKL5 deficiency disorder (CDD), sponsored by Zogenix, Inc.. Started Mar 2022; status: active, not recruiting.
02
Drugs
fenfluramine
03
Conditions
CDKL5 deficiency disorder (CDD)
Beyond the preview
Go deeper on NCT05064878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05064878.